The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
about
The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada.Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety.Advances in ovarian cancer therapy.First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
P2860
The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The Cost-Effectiveness of Beva ...... Evidence from the ICON7 Trial.
@en
The Cost-Effectiveness of Beva ...... Evidence from the ICON7 Trial.
@nl
type
label
The Cost-Effectiveness of Beva ...... Evidence from the ICON7 Trial.
@en
The Cost-Effectiveness of Beva ...... Evidence from the ICON7 Trial.
@nl
prefLabel
The Cost-Effectiveness of Beva ...... Evidence from the ICON7 Trial.
@en
The Cost-Effectiveness of Beva ...... Evidence from the ICON7 Trial.
@nl
P50
P1433
P1476
The Cost-Effectiveness of Beva ...... Evidence from the ICON7 Trial
@en
P2093
Adrian Cook
Mark Sculpher
P304
P356
10.1016/J.JVAL.2016.01.013
P577
2016-03-24T00:00:00Z